|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
gptkb:Madrigal_Pharmaceuticals
gptkb:Alder_Bio_Pharmaceuticals
Syndax Pharmaceuticals
Pediatric Rare Disease Portfolio
|
|
gptkbp:acquisition
|
gptkb:Amgen
|
|
gptkbp:awards
|
Best Places to Work
Top Workplaces
|
|
gptkbp:ceo
|
Tim Walbert
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:community_involvement
|
patient advocacy
research funding
healthcare initiatives
|
|
gptkbp:financial_performance
|
profitability
revenue growth
market capitalization
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
Tim Walbert
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Horizon Therapeutics
|
|
gptkbp:instruction_set
|
Phase 3 trials
multiple candidates
Phase 1 trials
Phase 2 trials
|
|
gptkbp:leadership
|
gptkb:CEO
gptkb:Board_of_Directors
|
|
gptkbp:market_position
|
gptkb:Europe
gptkb:Latin_America
gptkb:North_America
gptkb:Asia-Pacific
|
|
gptkbp:number_of_employees
|
over 1,000
|
|
gptkbp:partnership
|
gptkb:Duke_University
gptkb:University_of_Chicago
gptkb:Cleveland_Clinic
|
|
gptkbp:products
|
gptkb:Krystexxa
gptkb:Actimmune
gptkb:Ravicti
gptkb:Tepezza
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:Health_Canada
gptkb:TGA_Australia
gptkb:EMA
|
|
gptkbp:research_and_development
|
investment
|
|
gptkbp:research_focus
|
autoimmune diseases
inflammatory diseases
|
|
gptkbp:social_responsibility
|
sustainability initiatives
diversity and inclusion programs
community health programs
environmental impact reduction
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:HZNP
|
|
gptkbp:subsidiary
|
gptkb:Horizon_Pharma_USA,_Inc.
gptkb:Horizon_Therapeutics_Canada_Inc.
gptkb:Horizon_Therapeutics_Ireland_Ltd.
gptkb:Horizon_Therapeutics_UK_Ltd.
|
|
gptkbp:website
|
horizontherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|